Gain Therapeutics Statistics Share Statistics Gain Therapeutics has 35.95M
shares outstanding. The number of shares has increased by 17.27%
in one year.
Shares Outstanding 35.95M Shares Change (YoY) 17.27% Shares Change (QoQ) 12.9% Owned by Institutions (%) 9.8% Shares Floating 34.19M Failed to Deliver (FTD) Shares 5,000 FTD / Avg. Volume 1.28%
Short Selling Information The latest short interest is 210.92K, so 0.59% of the outstanding
shares have been sold short.
Short Interest 210.92K Short % of Shares Out 0.59% Short % of Float 0.61% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -2.42 and the forward
PE ratio is -2.31.
Gain Therapeutics's PEG ratio is
0.05.
PE Ratio -2.42 Forward PE -2.31 PS Ratio 0 Forward PS 1193.5 PB Ratio 6.73 P/FCF Ratio -2.62 PEG Ratio 0.05
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Gain Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.97,
with a Debt / Equity ratio of 0.09.
Current Ratio 2.97 Quick Ratio 2.97 Debt / Equity 0.09 Debt / EBITDA -0.03 Debt / FCF -0.03 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-887.44K Employee Count 23 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 536.82K Effective Tax Rate -2.7%
Stock Price Statistics The stock price has increased by 12.93% in the
last 52 weeks. The beta is 0.14, so Gain Therapeutics's
price volatility has been higher than the market average.
Beta 0.14 52-Week Price Change 12.93% 50-Day Moving Average 1.69 200-Day Moving Average 1.9 Relative Strength Index (RSI) 44.46 Average Volume (20 Days) 389,954
Income Statement
Revenue n/a Gross Profit -84.07K Operating Income -20.35M Net Income -20.41M EBITDA -19.79M EBIT -19.87M Earnings Per Share (EPS) -0.89
Full Income Statement Balance Sheet The company has 10.39M in cash and 653.01K in
debt, giving a net cash position of 9.73M.
Cash & Cash Equivalents 10.39M Total Debt 653.01K Net Cash 9.73M Retained Earnings -81.19M Total Assets 9.83M Working Capital 4.11M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -18.87M
and capital expenditures -22.49K, giving a free cash flow of -18.9M.
Operating Cash Flow -18.87M Capital Expenditures -22.49K Free Cash Flow -18.9M FCF Per Share -0.83
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
